Breast cancer is one of the most common forms of cancer for American women, coming in just second behind lung cancer. According to www.breastcancer.org, one in every eight women in the U.S. develops some form of breast cancer. Like any form of cancer, a delay in diagnosis or a misdiagnosis of cancer can have a negative effect on a patient’s outcome.
Once breast cancer is diagnosed, the typical treatment for breast cancer involves surgery, chemotherapy, and radiation. However, a new study unveiled at a Chicago meeting of the American Society of Clinical Oncology (ASCO) could change the standard for breast cancer treatment. TARGIT-A study is an international study of breast cancer clinical trials involving over 2,000 breast cancer patients. The participants were women 45 years-old and up who had been diagnosed with invasive ductal breast cancer and were undergoing breast-conserving surgery.
Traditionally patients who elect for breast-conserving surgery undergo whole breast external radiation therapy for up to 6 1/2 weeks following surgery. However, the TARGIT-A clinical trials studied the effects of targeted radiation administered during the surgery. The radiation is administered in a single dose and targets only the area of the breast with cancer instead of the whole breast. Half of the studies participants underwent the traditional post-op radiation while the other half received the targeted radiation therapy during surgery. The TARGIT-A study found that the targeted therapy group did somewhat better overall than the traditional radiation group.